Affimed Stock Forecast, Price & News

Affimed (NASDAQ:AFMD) Frequently Asked Questions

Is Affimed a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed or view top-rated stocks.

How has Affimed's stock price been impacted by COVID-19?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AFMD stock has increased by 134.1% and is now trading at $4.26.
View which stocks have been most impacted by COVID-19.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Affimed.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analysts' expectations of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 132.18%. During the same quarter in the prior year, the firm posted ($0.08) earnings per share.
View Affimed's earnings history.

What price target have analysts set for AFMD?

7 brokers have issued 12 month price targets for Affimed's shares. Their forecasts range from $10.00 to $15.00. On average, they expect Affimed's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for Affimed or view top-rated stocks among Wall Street analysts.

Who are Affimed's key executives?

Affimed's management team includes the following people:

• Adolf Hoess, Chief Executive Officer
• Wolfgang Fischer, Chief Operating Officer
• Angus W. Smith, Chief Financial Officer
• Andreas Harstrick, Chief Medical Officer
• Arndt Schottelius, Chief Scientific Officer

Who are some of Affimed's key competitors?

Some companies that are related to Affimed include Cassava Sciences (SAVA), Protagonist Therapeutics (PTGX), Xenon Pharmaceuticals (XENE), Verve Therapeutics (VERV), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Dynavax Technologies (DVAX), Morphic (MORF), IVERIC bio (ISEE), Zogenix (ZGNX), Bicycle Therapeutics (BCYC), Erasca (ERAS), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV) and Lyell Immunopharma (LYEL).
View all of AFMD's competitors.

What other stocks do shareholders of Affimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Harbor Investment Advisory LLC (0.21%), Lenox Wealth Advisors LLC (0.01%) and Cutler Group LP (0.00%).

Which institutional investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Harbor Investment Advisory LLC.

Which institutional investors are buying Affimed stock?

AFMD stock was bought by a variety of institutional investors in the last quarter, including Lenox Wealth Advisors LLC, and Cutler Group LP.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $4.26.

How much money does Affimed make?

Affimed has a market capitalization of $418.70 million and generates $32.39 million in revenue each year. The biopharmaceutical company earns $-47.25 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 158 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

Where are Affimed's headquarters?

Affimed is headquartered at TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 496221674360, via email at [email protected], or via fax at 49-6221-653-0777.